Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) shares shot up 6.9% during mid-day trading on Friday . The stock traded as high as $1.84 and last traded at $1.69. 10,292 shares traded hands during trading, a decline of 64% from the average session volume of 28,922 shares. The stock had previously closed at $1.58.
Humacyte Price Performance
The stock has a 50 day simple moving average of $1.84 and a 200 day simple moving average of $1.97.
About Humacyte
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Read More
- Five stocks we like better than Humacyte
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Disney’s Magic Strategy: Reinventing the House of Mouse
- What is a Secondary Public Offering? What Investors Need to Know
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- 3 REITs to Buy and Hold for the Long Term
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
